6th Jan 2022 12:12
Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Completes testing requirements of a multi-centre validation study for its Clarava and Tuteva products. The company explains that this means sufficient numbers of participants have completed the required follow-up to outcomes assessment which are required for the full data analysis and clinical study report to be conducted in the first quarter of 2022.
Clarava and Tuteva aim to understand how a patient will respond and is responding to kidney transplantation. Clarava is a pre-transplant test, while Tuteva is a post-transplant test,
Current stock price: 54.60 pence, up 2.1% in London
Year-to-date change: up 3%
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Verici Dx